Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Preliminary evaluation of fecal fatty acid concentrations in cats with chronic kidney disease and correlation with indoxyl sulfate and p-cresol sulfate.

Summers S, Quimby JM, Phillips RK, Stockman J, Isaiah A, Lidbury JA, Steiner JM, Suchodolski J.

J Vet Intern Med. 2019 Nov 6. doi: 10.1111/jvim.15634. [Epub ahead of print]

2.

Pilot study of side effects and serum and urine concentrations of amoxicillin-clavulanic acid in azotemic and non-azotemic cats.

Benson KK, Quimby JM, Dowers KL, Sieberg LG, Daniels JB, Langston CE, Lunghofer PJ, Gustafson DL.

J Feline Med Surg. 2019 Oct 29:1098612X19881537. doi: 10.1177/1098612X19881537. [Epub ahead of print]

PMID:
31660773
3.

Intra- and inter-rater reliability in the cross-sectional area of feline lumbar epaxial musculature evaluated via abdominal CT scan.

Rayhel LH, Quimby JM, Green EM, Parker VJ, Bai S.

J Feline Med Surg. 2019 Oct 29:1098612X19880997. doi: 10.1177/1098612X19880997. [Epub ahead of print]

PMID:
31660772
4.

Rational synthesis of an atomically precise carboncone under mild conditions.

Zhu ZZ, Chen ZC, Yao YR, Cui CH, Li SH, Zhao XJ, Zhang Q, Tian HR, Xu PY, Xie FF, Xie XM, Tan YZ, Deng SL, Quimby JM, Scott LT, Xie SY, Huang RB, Zheng LS.

Sci Adv. 2019 Aug 23;5(8):eaaw0982. doi: 10.1126/sciadv.aaw0982. eCollection 2019 Aug.

5.

Retrospective study of the efficacy of oral potassium supplementation in cats with kidney disease.

Sieberg LG, Quimby JM.

J Feline Med Surg. 2019 Jul 15:1098612X19862084. doi: 10.1177/1098612X19862084. [Epub ahead of print]

PMID:
31304869
6.

Assessment of compounded transdermal mirtazapine as an appetite stimulant in cats with chronic kidney disease.

Quimby JM, Benson KK, Summers SC, Saffire A, Herndon AK, Bai S, Gustafson DL.

J Feline Med Surg. 2019 Jun 4:1098612X19851303. doi: 10.1177/1098612X19851303. [Epub ahead of print]

PMID:
31161850
7.

Stem Cell Therapy.

Quimby JM.

Vet Clin North Am Small Anim Pract. 2019 Mar;49(2):223-231. doi: 10.1016/j.cvsm.2018.10.001. Epub 2018 Dec 24. Review.

PMID:
30591191
8.

The fecal microbiome and serum concentrations of indoxyl sulfate and p-cresol sulfate in cats with chronic kidney disease.

Summers SC, Quimby JM, Isaiah A, Suchodolski JS, Lunghofer PJ, Gustafson DL.

J Vet Intern Med. 2019 Mar;33(2):662-669. doi: 10.1111/jvim.15389. Epub 2018 Dec 18.

9.

A double-blind, placebo-controlled, randomized study to evaluate the weight gain drug, mirtazapine transdermal ointment, in cats with unintended weight loss.

Poole M, Quimby JM, Hu T, Labelle D, Buhles W.

J Vet Pharmacol Ther. 2019 Mar;42(2):179-188. doi: 10.1111/jvp.12738. Epub 2018 Dec 2.

PMID:
30506924
10.

In vivo and in vitro assessment of mirtazapine pharmacokinetics in cats with liver disease.

Fitzpatrick RL, Quimby JM, Benson KK, Ramirez D, Sieberg LG, Wittenburg LA, Gustafson DL.

J Vet Intern Med. 2018 Nov;32(6):1951-1957. doi: 10.1111/jvim.15237. Epub 2018 Oct 11.

11.

Single and multiple dose pharmacokinetics of a novel mirtazapine transdermal ointment in cats.

Buhles W, Quimby JM, Labelle D, Williams VS.

J Vet Pharmacol Ther. 2018 Oct;41(5):644-651. doi: 10.1111/jvp.12691. Epub 2018 Jul 13.

PMID:
30004120
12.

Mesenchymal stem cell therapy in cats: Current knowledge and future potential.

Quimby JM, Borjesson DL.

J Feline Med Surg. 2018 Mar;20(3):208-216. doi: 10.1177/1098612X18758590. Review.

PMID:
29478398
13.

Survey of owner subcutaneous fluid practices in cats with chronic kidney disease.

Cooley CM, Quimby JM, Caney SM, Sieberg LG.

J Feline Med Surg. 2018 Oct;20(10):884-890. doi: 10.1177/1098612X17732677. Epub 2017 Sep 26.

PMID:
28948902
14.

Preliminary pharmacokinetics of intravenous and subcutaneous dolasetron and pharmacodynamics of subcutaneous dolasetron in healthy cats.

Herndon AK, Quimby JM, Sieberg LG, Davis L, Caress AL, Ligas S, Hansen RJ, Wittenburg LA, Gustafson DL.

J Feline Med Surg. 2018 Aug;20(8):721-727. doi: 10.1177/1098612X17729310. Epub 2017 Sep 14.

PMID:
28905667
15.

Assessment of absorption of transdermal ondansetron in normal research cats.

Zajic LB, Herndon AK, Sieberg LG, Caress AL, Morgan PK, Hansen RJ, Wittenburg LA, Gustafson DL, Quimby JM.

J Feline Med Surg. 2017 Dec;19(12):1245-1248. doi: 10.1177/1098612X16688807. Epub 2017 Jan 23.

PMID:
28112563
16.

Comparison of proliferative and immunomodulatory potential of adipose-derived mesenchymal stem cells from young and geriatric cats.

Zajic LB, Webb TL, Webb P, Coy JW, Dow SW, Quimby JM.

J Feline Med Surg. 2017 Oct;19(10):1096-1102. doi: 10.1177/1098612X16680703. Epub 2016 Dec 5.

PMID:
27913779
17.

REPEATABILITY AND RELIABILITY OF GLOMERULAR FILTRATION RATE DETERMINATION VIA GAMMA CAMERA UPTAKE OF TC-99M-DTPA IN CATS WITH CHRONIC KIDNEY DISEASE.

Felumlee AE, Marolf AJ, Randall EK, Bachand AM, Quimby JM.

Vet Radiol Ultrasound. 2017 Jan;58(1):90-99. doi: 10.1111/vru.12435. Epub 2016 Oct 23.

PMID:
27774745
18.

Drug exposure and clinical effect of transdermal mirtazapine in healthy young cats: a pilot study.

Benson KK, Zajic LB, Morgan PK, Brown SR, Hansen RJ, Lunghofer PJ, Wittenburg LA, Gustafson DL, Quimby JM.

J Feline Med Surg. 2017 Oct;19(10):998-1006. doi: 10.1177/1098612X16667168. Epub 2016 Sep 1.

19.

Update on Medical Management of Clinical Manifestations of Chronic Kidney Disease.

Quimby JM.

Vet Clin North Am Small Anim Pract. 2016 Nov;46(6):1163-81. doi: 10.1016/j.cvsm.2016.06.004. Review.

PMID:
27593576
20.

Renal pelvic and ureteral ultrasonographic characteristics of cats with chronic kidney disease in comparison with normal cats, and cats with pyelonephritis or ureteral obstruction.

Quimby JM, Dowers K, Herndon AK, Randall EK.

J Feline Med Surg. 2017 Aug;19(8):784-790. doi: 10.1177/1098612X16656910. Epub 2016 Jul 7.

PMID:
27389573
21.

Limited sampling pharmacokinetics of subcutaneous ondansetron in healthy geriatric cats, cats with chronic kidney disease, and cats with liver disease.

Fitzpatrick RL, Wittenburg LA, Hansen RJ, Gustafson DL, Quimby JM.

J Vet Pharmacol Ther. 2016 Aug;39(4):350-5. doi: 10.1111/jvp.12286. Epub 2015 Dec 14.

PMID:
26667224
22.

Intravenous adipose-derived mesenchymal stem cell therapy for the treatment of feline asthma: a pilot study.

Trzil JE, Masseau I, Webb TL, Chang CH, Dodam JR, Liu H, Quimby JM, Dow SW, Reinero CR.

J Feline Med Surg. 2016 Dec;18(12):981-990. Epub 2015 Sep 17.

PMID:
26384398
23.

Bilirubin Encephalopathy in a Domestic Shorthair Cat With Increased Osmotic Fragility and Cholangiohepatitis.

Contreras ET, Giger U, Malmberg JL, Quimby JM, Schaffer PA.

Vet Pathol. 2016 May;53(3):629-32. doi: 10.1177/0300985815603433. Epub 2015 Sep 9.

24.

Mirtazapine toxicity in cats: retrospective study of 84 cases (2006-2011).

Ferguson LE, McLean MK, Bates JA, Quimby JM.

J Feline Med Surg. 2016 Nov;18(11):868-874. doi: 10.1177/1098612X15599026. Epub 2016 Jul 10.

PMID:
26228539
25.

Searching for biomarkers in feline chronic kidney disease: A new frontier.

Quimby JM.

Vet J. 2015 Oct;206(1):3-4. doi: 10.1016/j.tvjl.2015.05.005. Epub 2015 May 18. No abstract available.

PMID:
26123025
26.

Novel treatment strategies for feline chronic kidney disease: A critical look at the potential of mesenchymal stem cell therapy.

Quimby JM, Dow SW.

Vet J. 2015 Jun;204(3):241-6. doi: 10.1016/j.tvjl.2015.04.007. Epub 2015 Apr 9. Review.

PMID:
25933829
27.

Assessment of intravenous adipose-derived allogeneic mesenchymal stem cells for the treatment of feline chronic kidney disease: a randomized, placebo-controlled clinical trial in eight cats.

Quimby JM, Webb TL, Randall E, Marolf A, Valdes-Martinez A, Dow SW.

J Feline Med Surg. 2016 Feb;18(2):165-71. doi: 10.1177/1098612X15576980. Epub 2015 Mar 17.

PMID:
25784460
28.

Feline chronic kidney disease: understanding pathophysiology is the key to development of new treatments.

Quimby JM.

Vet J. 2015 Mar;203(3):265-6. doi: 10.1016/j.tvjl.2014.12.019. Epub 2014 Dec 24. No abstract available.

PMID:
25624188
29.

Evaluation of the effects of hospital visit stress on physiologic variables in dogs.

Bragg RF, Bennett JS, Cummings A, Quimby JM.

J Am Vet Med Assoc. 2015 Jan 15;246(2):212-5. doi: 10.2460/javma.246.2.212.

PMID:
25554937
30.

A comparison of biochemical and histopathologic staging in cats with chronic kidney disease.

McLeland SM, Cianciolo RE, Duncan CG, Quimby JM.

Vet Pathol. 2015 May;52(3):524-34. doi: 10.1177/0300985814561095. Epub 2014 Dec 16.

PMID:
25516066
31.

Chronic use of maropitant for the management of vomiting and inappetence in cats with chronic kidney disease: a blinded, placebo-controlled clinical trial.

Quimby JM, Brock WT, Moses K, Bolotin D, Patricelli K.

J Feline Med Surg. 2015 Aug;17(8):692-7. doi: 10.1177/1098612X14555441. Epub 2014 Oct 21.

PMID:
25336450
32.

Long-term evaluation of mesenchymal stem cell therapy in a feline model of chronic allergic asthma.

Trzil JE, Masseau I, Webb TL, Chang CH, Dodam JR, Cohn LA, Liu H, Quimby JM, Dow SW, Reinero CR.

Clin Exp Allergy. 2014 Dec;44(12):1546-57. doi: 10.1111/cea.12411.

33.

Relationship among serum creatinine, serum gastrin, calcium-phosphorus product, and uremic gastropathy in cats with chronic kidney disease.

McLeland SM, Lunn KF, Duncan CG, Refsal KR, Quimby JM.

J Vet Intern Med. 2014 May-Jun;28(3):827-37. doi: 10.1111/jvim.12342. Epub 2014 Mar 14.

34.

Oral, subcutaneous, and intravenous pharmacokinetics of ondansetron in healthy cats.

Quimby JM, Lake RC, Hansen RJ, Lunghofer PJ, Gustafson DL.

J Vet Pharmacol Ther. 2014 Aug;37(4):348-53. doi: 10.1111/jvp.12094. Epub 2013 Dec 16.

35.

Mirtazapine as an appetite stimulant and anti-emetic in cats with chronic kidney disease: a masked placebo-controlled crossover clinical trial.

Quimby JM, Lunn KF.

Vet J. 2013 Sep;197(3):651-5. doi: 10.1016/j.tvjl.2013.05.048. Epub 2013 Jul 6.

PMID:
23838205
36.

Feline chronic kidney disease is associated with shortened telomeres and increased cellular senescence.

Quimby JM, Maranon DG, Battaglia CL, McLeland SM, Brock WT, Bailey SM.

Am J Physiol Renal Physiol. 2013 Aug 1;305(3):F295-303. doi: 10.1152/ajprenal.00527.2012. Epub 2013 May 29.

38.

Subcutaneous fluid port-associated soft tissue sarcoma in a cat.

McLeland SM, Imhoff DJ, Thomas M, Powers BE, Quimby JM.

J Feline Med Surg. 2013 Oct;15(10):917-20. doi: 10.1177/1098612X13478267. Epub 2013 Feb 14.

PMID:
23413270
39.

Urinary cytokine levels in apparently healthy cats and cats with chronic kidney disease.

Habenicht LM, Webb TL, Clauss LA, Dow SW, Quimby JM.

J Feline Med Surg. 2013 Feb;15(2):99-104. doi: 10.1177/1098612X12461007. Epub 2012 Sep 18.

PMID:
22989558
40.

In vitro comparison of feline bone marrow-derived and adipose tissue-derived mesenchymal stem cells.

Webb TL, Quimby JM, Dow SW.

J Feline Med Surg. 2012 Feb;14(2):165-8. doi: 10.1177/1098612X11429224.

PMID:
22314096
41.

The pharmacokinetics of mirtazapine in cats with chronic kidney disease and in age-matched control cats.

Quimby JM, Gustafson DL, Lunn KF.

J Vet Intern Med. 2011 Sep-Oct;25(5):985-9. doi: 10.1111/j.1939-1676.2011.00780.x. Epub 2011 Aug 30.

42.

Evaluation of the effects of hospital visit stress on physiologic parameters in the cat.

Quimby JM, Smith ML, Lunn KF.

J Feline Med Surg. 2011 Oct;13(10):733-7. doi: 10.1016/j.jfms.2011.07.003. Epub 2011 Aug 12.

PMID:
21839664
44.

Evaluation of intrarenal mesenchymal stem cell injection for treatment of chronic kidney disease in cats: a pilot study.

Quimby JM, Webb TL, Gibbons DS, Dow SW.

J Feline Med Surg. 2011 Jun;13(6):418-26. doi: 10.1016/j.jfms.2011.01.005. Epub 2011 Feb 22.

PMID:
21334237
45.

Highly charged supramolecular oligomers based on the dimerization of corannulene tetraanion.

Eisenberg D, Quimby JM, Jackson EA, Scott LT, Shenhar R.

Chem Commun (Camb). 2010 Dec 21;46(47):9010-2. doi: 10.1039/c0cc03965a. Epub 2010 Nov 5.

PMID:
21057679
46.

Studies on the pharmacokinetics and pharmacodynamics of mirtazapine in healthy young cats.

Quimby JM, Gustafson DL, Samber BJ, Lunn KF.

J Vet Pharmacol Ther. 2011 Aug;34(4):388-96. doi: 10.1111/j.1365-2885.2010.01244.x. Epub 2010 Oct 24.

PMID:
20969604
47.

The bicorannulenyl dianion: a charged overcrowded ethylene.

Eisenberg D, Jackson EA, Quimby JM, Scott LT, Shenhar R.

Angew Chem Int Ed Engl. 2010 Oct 4;49(41):7538-42. doi: 10.1002/anie.201002515. No abstract available.

PMID:
20814993
48.

Adverse neurologic events associated with voriconazole use in 3 cats.

Quimby JM, Hoffman SB, Duke J, Lappin MR.

J Vet Intern Med. 2010 May-Jun;24(3):647-9. doi: 10.1111/j.1939-1676.2010.00504.x. Epub 2010 Apr 6.

49.

Routine analysis and characterization of highly insoluble polycyclic aromatic compounds by direct analysis in real time mass spectrometry (DART).

Domin MA, Steinberg BD, Quimby JM, Smith NJ, Greene AK, Scott LT.

Analyst. 2010 Apr;135(4):700-4. doi: 10.1039/b923300h. Epub 2010 Jan 12.

PMID:
20309443
50.

Comparison of digital rectal and microchip transponder thermometry in cats.

Quimby JM, Olea-Popelka F, Lappin MR.

J Am Assoc Lab Anim Sci. 2009 Jul;48(4):402-4.

Supplemental Content

Loading ...
Support Center